Other languages Ocean Biomedical, Inc.

Equities

OCEA

US67644C1045

Market Closed - Nasdaq Other stock markets 01:30:00 15/06/2024 am IST			5-day change	1st Jan Change
1.41 ^USD	-5.37%		-2.42%	+113.64%

30/05	Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down	MT
15/04	Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down	30/05
Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/04
Ocean Biomedical, Inc. Appoints Amy Griffith as Director	09/03
Ocean Biomedical Announces Publication of Breast Cancer Research Uncovering New Tumor Suppression Pathway for its Proprietary Anti-Chi3L1 Antibody	05/12
Ocean Biomedical Says Potential Treatment for Advanced Solid Tumors Yields 'Highly Compelling' Preclinical Data	14/11
Ocean Biomedical, Inc. Announces Positive Preclinical Oncology Data for Vron 0300, Presented At Sitc 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics	14/11
Virion Therapeutics and Joint Venture Partner, Ocean Biomedical Announces First Patients Dosed with Novel Immunotherapy Evaluating A Functional Cure for Chronic Hepatitis B Virus Infection	26/23/26
Ocean Biomedical, Inc. Announces Resignation of Jerome Ringo as Member of Board of Directors	13/23/13
Ocean Biomedical, Virion Therapeutics Form Joint Venture to Seek Cures for Cancer, Infectious Diseases	12/23/12
Ocean Biomedical Says Data Show Antibody Candidate Can Restore Treatment Sensitivity to AstraZeneca's Lung Cancer Drug	03/23/03
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to Astrazeneca?s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers	03/23/03
Ocean Biomedical Secures US Patent for Anti-Chitinase 1 Small Molecule Candidate	29/23/29
Ocean Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Ocean Biomedical, Inc. Provides Latest Updates on Its Broad Programs in Malaria, Fibrosis, and Multiple Cancers	10/23/10
Ocean Biomedical Says Vaccine Candidate Led to Over 90% Killing of Malaria Parasites in Non-Human Primates	11/23/11
Ocean Biomedical, Inc. Focuses its Multi-Ponged Malaria Program to Address the Chronic Malaria Crisis in Sub-Saharan Africa	11/23/11
Ocean Biomedical Receives European Patent Notice for Idiopathic Pulmonary Fibrosis Treatment Candidate	23/23/23
Ocean Biomedical Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery to Europe	23/23/23
Ocean Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25
Top Midday Gainers	23/23/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ocean Biomedical, Inc.

Equities

OCEA

US67644C1045

Other languages

Filters